Minoryx Therapeutics
https://www.minoryx.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Minoryx Therapeutics
Two Avian Flu Vaccines Among 10 New Products To Get EMA Nod
The European Medicines Agency has OKd two new H5N1 jabs, including a pandemic preparedness vaccine intended for use only if a flu pandemic is declared. Eight other products are also heading for EU-wide approval.
EMA Turns Down Minoryx’s Orphan Drug Nezglyal & Apellis’ Syfovre, OKs Three Others
The European Medicines Agency has recommended against the pan-EU marketing approval of two new medicines, while three others received positive opinions on marketing authorization.
Crucial Meetings With EMA Due For Travere/Vifor’s Sparsentan & Minoryx’s Leriglitazone
Developers of three new drugs, including two orphan medicines, that are nearing the final stages of their EU regulatory review cycle could be asked to explain why the European Medicines Agency should recommend approval of their products.
TG Therapeutics Briumvi Deal Fails To Impress The Market
Linking up with Germany’s Neuraxpharm to sell the multiple sclerosis drug Briumvi in Europe and elsewhere has gone down badly with investors but the bashing that TG Therapeutics’ shares has taken seems excessive.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Minoryx Therapeuctics BE, SA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice